Biopharmaceutical company developing and commercializing therapies for endocrine and other diseases.
2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Based on 2 scored insights about Xeris Biopharma Holdings, Inc..
The 1 sources with the most insights about Xeris Biopharma Holdings, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Mentioned as a company with revenue and a pipeline, including a drug associated with Cushing’s syndrome. Trading around earnings was floated, but no clear recommendation or outlook was given.
The speaker described the company as having revenue and a pipeline and called it not such a bad thing, but gave no specific recommendation.
Mentioned as a company with revenue and a pipeline, including a drug associated with Cushing’s syndrome. Trading around earnings was floated, but no clear recommendation or outlook was given.
The speaker described the company as having revenue and a pipeline and called it not such a bad thing, but gave no specific recommendation.
Other assets that creators frequently mention in the same content as Xeris Biopharma Holdings, Inc..
The most active sources covering Xeris Biopharma Holdings, Inc. (XERS) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Xeris Biopharma Holdings, Inc. (XERS) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Xeris Biopharma Holdings, Inc. (XERS) most frequently also discuss OSUR, ZURA, NAUT, PLTR, HUMA. See the "Discussed alongside" section above for full asset pages.